Amgen Inc. (AMGN) Covered Calls

Amgen Inc. covered calls Amgen Inc. is a leading biotechnology company that discovers and delivers innovative human therapeutics for serious illnesses. Its diverse portfolio spans oncology, rare disease, and inflammation, featuring key brands like Repatha and Enbrel. Following its 2026 acquisition of Dark Blue Therapeutics, the company has strengthened its oncology pipeline. Amgen is also a global leader in biosimilars and is advancing next-generation metabolic treatments for obesity and diabetes.

You can sell covered calls on Amgen Inc. to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for AMGN (prices last updated Fri 4:16 PM ET):

Amgen Inc. (AMGN) Stock Quote
Last Change Bid Ask Volume P/E Market Cap
369.19 +2.99 368.00 369.15 2.2M 28 197
Covered Calls For Amgen Inc. (AMGN)
Expiration Strike Call Bid Net Debit Return
If Flat		 Annualized
Return If Flat
Feb 20 370 3.70 365.45 1.0% 45.6%
Mar 20 370 10.15 359.00 2.8% 28.4%
Subscribers get access to the full covered call chain, and more features.

Want to make money with covered calls?  Sign Up For A Free Trial

Core Business and Products

Amgen operates as a science-first biopharmaceutical leader, utilizing advanced human genetics to identify and validate therapeutic targets. By 2026, the company has successfully integrated its Horizon Therapeutics acquisition, establishing a dominant pillar in rare diseases. Their primary product categories include:

  1. General Medicine and Inflammation: High-growth products like Repatha for cardiovascular health and Tezspire for severe asthma, alongside the established immunology franchise led by Enbrel.
  2. Rare Disease: A specialized portfolio featuring Tepezza for thyroid eye disease and Krystexxa for chronic gout, which have become central to the company’s revenue growth.
  3. Oncology: A diverse lineup including Imdelltra for lung cancer and Blincyto, further bolstered by the 2026 acquisition of Dark Blue Therapeutics.
  4. Biosimilars: A market-leading division providing cost-effective alternatives like Wezlana (biosimilar to Stelara) and Pavblu (biosimilar to Eylea).

Competitive Landscape

Amgen competes in an increasingly crowded global market against both large-cap pharmaceutical giants and specialized biotech firms. In the inflammation and oncology sectors, its primary rivals include AbbVie, Pfizer, and Merck & Co.. In the burgeoning obesity and metabolic space, it faces stiff competition from market leaders Eli Lilly and Novo Nordisk. For its rare disease segment, it contends with Regeneron Pharmaceuticals and Vertex Pharmaceuticals. Additionally, the company faces "accelerated sales erosion" on legacy products like Prolia as biosimilar competitors from Sandoz and other generic manufacturers enter the market.

Strategic Outlook and Innovation

The 2026 strategic roadmap for Amgen is defined by "disciplined data generation," with all eyes on the MARITIME Phase 3 program for its obesity candidate, MariTide. Amgen is positioning MariTide as a differentiated, monthly-or-less injectable that could disrupt the current weekly-dosing metabolic market. Innovation efforts are also centered on the convergence of AI and biology, utilizing generative AI models to compress drug discovery timelines and optimize clinical trial enrollment. The company is investing over half a billion dollars in its new Center for Science and Innovation to enhance its protein engineering capabilities. By balancing its high-margin rare disease growth with a defensive biosimilar strategy, Amgen aims to offset patent cliffs for legacy brands while funding its transition into the next era of multispecific medicines and RNA-based cardiovascular treatments.